April 14, 2022
Life Sciences
  • Pfizer Inc/BioNTech SE said a booster dose of their COVID-19 vaccine strengthened the immune response against COVID-19 and the omicron variant among children ages 5 to 11 in a small trial. The biotech company said they will ask the Food and Drug Administration (FDA) to authorize another shot for young kids “in the coming days.” If it’s granted, it could make another 28 million children eligible for booster shots. (Articles here and here)